Want to see VCYT full AI Analyst Report?
VCYT Stock Chart & Stats
$33.80
$0.68(1.60%)
At close: 4:00 PM EST
$33.80
$0.68(1.60%)
Day’s Range― - ―
52-Week Range$22.61 - $60.91
Previous CloseN/A
Volume253.49K
Average Volume (3M)1.32M
Market Cap
$4.55B
Enterprise Value$3.87B
Total Cash (Recent Filing)$439.06M
Total Debt (Recent Filing)$39.33M
Price to Earnings (P/E)51.5
Beta1.18
Next Earnings
Aug 11, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding79,792,650
10 Day Avg. Volume1,531,057
30 Day Avg. Volume1,320,928
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue7.14
Enterprise Value/Gross Profit10.01
Enterprise Value/Ebitda34.47
Forecast
1Y Price Target
$50.43Price Target Upside49.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)1.83
Revenue Forecast (FY)$586.99M
Bulls Say, Bears Say
Bulls Say
Strong Cash Position & GenerationA large cash stockpile and positive operating cash flow provide durable financial flexibility to fund commercial rollouts (Prosigna, TruMRD), absorb reimbursement timing variability, invest in R&D and sales, and avoid near-term financing needs, supporting multi-quarter execution.
Low Leverage / Conservative Balance SheetVery low debt levels reduce refinancing and interest-rate risk, enabling the company to prioritize organic investment, M&A or strategic partnerships without pressure to cut R&D or commercial spend, which supports sustained product development and commercialization over months.
Margin Expansion And Sustained ProfitabilityMaterial margin improvement and a profitable, cash-generative model indicate scalable lab economics and pricing power. Higher gross and EBITDA margins create durable ability to reinvest in growth initiatives while maintaining profitability through moderate revenue swings.
Bears Say
Revenue Growth DecelerationA slowdown from prior high-growth rates reduces the runway for operating-leverage gains and increases dependence on new-product launches and greater market penetration to restore top-line momentum; sustained slower growth can constrain long-term margin uplift.
Binary Clinical Trial Risk (OPTIMA/ENZIMET)Key product commercialization and guideline inclusion hinge on binary trial outcomes. Negative or delayed readouts could materially postpone label expansion, reimbursement, and physician adoption, undermining projected revenue contributions from Prosigna and Decipher-related indications.
Guideline & Reimbursement Timing UncertaintyEven with positive data, delayed guideline updates or payer coverage decisions can defer widespread adoption and cash collections. Combined with PPC variability and seasonal no-result rate impacts, this creates durable timing risk to revenue realization and visibility over several quarters.
Veracyte News
VCYT FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was $22.61 and its highest was $60.91 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is $4.55B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Aug 11, 2026 which is in 35 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on May 05, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.334 by $0.186.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.43.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 79,792,650 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of $0.52 in its last earnings report, beating expectations of $0.334. Following the earnings report the stock price went up 24.932%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$50.43 (49.20% Upside)
$50.43 (49.20% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.96%
12-Months-Change
Fundamentals
Return on Equity
6.86%
Trailing 12-Months
Asset Growth
9.20%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$50.43
▲(49.20% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
1.81% Insiders
34.98% Mutual Funds
24.09% Other Institutional Investors
1.60% Public Companies and
Individual Investors